People · Operator
Named in public records as an officer, director or promoter · active 2018–2019 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Revolution Medicines, Inc. | — | Pharmaceuticals | Series D+ | $204.2M | $3.5B | 2018 |
Steve A. Kelsey at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Steve A. Kelsey on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Alexis A. Borisy | 1 | 3 |
| Neil A. Exter | 1 | 3 |
| Mark A. Goldsmith | 1 | 2 |
| Barbara A. Weber | 1 | 1 |
| Thilo A. Schroeder | 1 | 1 |
| Vincent A. Miller | 1 | 1 |
| Laurence A. Lasky | 1 | 1 |
| Margaret A. Horn | 1 | 1 |
| Elizabeth A. Anderson | 1 | 1 |
| Luan A. Wilfong | 1 | 1 |
| Ryan A. Martins | 1 | 1 |
| Michael A. Bonney | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.